Nektar Therapeutics PT Raised to $18.00 at Brean Capital (NKTR)
Research analysts at Brean Capital lifted their target price on shares of Nektar Therapeutics (NASDAQ:NKTR) from $14.00 to $18.00 in a report released on Monday, American Banking News.com reports. Brean Capital’s price objective points to a potential upside of 32.35% from the company’s current price.
Nektar Therapeutics (NASDAQ:NKTR) opened at 13.60 on Monday. Nektar Therapeutics has a 52-week low of $8.64 and a 52-week high of $14.47. The stock has a 50-day moving average of $12.24 and a 200-day moving average of $11.68. The company’s market cap is $1.579 billion.
Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.22) by $0.08. The company had revenue of $60.91 million for the quarter, compared to the consensus estimate of $54.34 million. The company’s revenue for the quarter was up 230.8% on a year-over-year basis. On average, analysts predict that Nektar Therapeutics will post $-1.16 earnings per share for the current fiscal year.
NKTR has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of Nektar Therapeutics from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, January 7th. They now have a $12.90 price target on the stock. Analysts at Piper Jaffray initiated coverage on shares of Nektar Therapeutics in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $14.74.
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.